Bristol Re-Restates; Income Taxes, "Grants" May Be Ongoing Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
The company adjusts reported 2003 revenues by about $200 mil. Although impact of Bristol's second restatement is smaller than the first, tax issues and treatment of "grants" as advertising expenses could hint at deeper issues.
You may also be interested in...
Bristol's $300 Mil. Settlement Leaves $170 Mil. In Reserve For Wholesaler Litigation
The company settles a securities class action related to wholesaler inventory accounting practices and Bristol's investment in ImClone's oncologic Erbitux. The settlement awaits final approval by Manhattan district court.
Bristol's $300 Mil. Settlement Leaves $170 Mil. In Reserve For Wholesaler Litigation
The company settles a securities class action related to wholesaler inventory accounting practices and Bristol's investment in ImClone's oncologic Erbitux. The settlement awaits final approval by Manhattan district court.
Bristol Takes $455 Mil. Litigation Charge, Higher Than Earlier Expectations
Bristol-Myers Squibb increased its litigation reserves to $455 mil. in the second quarter, a charge that is $55 mil. higher than earlier expectations